ArticleScientific reports2025
Cost-effectiveness of finotonlimab plus chemotherapy versus chemotherapy alone for recurrent or metastatic head and neck cancer in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent or metastatic head and neck cancer (R/M HNSCC) is highly prevalent in Southern China and Southeast Asia. Although immune checkpoint inhibitors such as finotonlimab combined with chemotherapy have shown promising survival benefits, their high costs pose challenges for healthcare systems in resource-constrained settings. This study aims to evaluate the cost-effectiveness of finotonlimab plus chemotherapy versus chemotherapy alone as the first-line treatment for R/M HNSCC from the perspective of the Chinese healthcare payer.
methodsA 3-health-state Markov model was developed to simulate long-term clinical and economic outcomes for patients receiving either finotonlimab with cisplatin and 5-fluorouracil (finotonlimab + C5F) or placebo with C5F (Placebo + C5F). Survival data were reconstructed from published clinical trials and extrapolated using parametric models. Direct medical costs, health state utilities, and adverse event disutilities were sourced from the literature. The primary outcome was the incremental cost-effectiveness ratio (ICER), with a willingness-to-pay (WTP) threshold of $39,835.62 per quality-adjusted life year (QALY) gained. Sensitivity and scenario analyses were conducted to explore uncertainty.
resultsThe finotonlimab + C5F group yielded 1.048 QALYs at a cost of $51,453.4, while the Placebo + C5F group yielded 0.788 QALYs at $22,020.2. The ICER was $113,051.4 per QALY gained, exceeding the WTP threshold. Scenario analysis revealed persistently high ICERs in finotonlimab + C5F group across different time horizons (2, 8, 10 years). One-way sensitivity analysis identified drug cost and PFS utility as the most influential parameters. Probabilistic analysis showed 0% probability of cost-effectiveness at the WTP threshold.
conclusionAlthough finotonlimab combined with chemotherapy provides clinical benefits for patients with R/M HNSCC, it is not cost-effective at current pricing in China. Substantial price reductions, biomarker-guided patient selection, and inclusion in national reimbursement programs may improve its economic viability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.